5'-Deoxy-5-fluorouridine (BioDeep_00000009379)
Secondary id: BioDeep_00000858604
human metabolite Endogenous blood metabolite
代谢物信息卡片
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one
化学式: C9H11FN2O5 (246.06519680000002)
中文名称: 5-脱氧-5-氟尿苷
谱图信息:
最多检出来源 Homo sapiens(blood) 4.34%
分子结构信息
SMILES: CC1C(C(C(O1)N2C=C(C(=O)NC2=O)F)O)O
InChI: InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)
描述信息
5-Deoxy-5-fluorouridine is a metabolite of capecitabine. Capecitabine (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. (Wikipedia)
D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D019167 - Appetite Stimulants
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
Same as: D01309
Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs[1][2][3].
同义名列表
19 个代谢物同义名
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one; 1-(5-Deoxypentofuranosyl)-5-fluoropyrimidine-2,4(1h,3h)-dione; 1-(beta-D-5-Desoxyribofuranoxyl)-5-fluoruracil; 1-(b-D-5-Desoxyribofuranoxyl)-5-fluoruracil; 1-(Β-D-5-desoxyribofuranoxyl)-5-fluoruracil; 5-Deoxy-5-fluorouridine; 5-Fluoro-5-deoxyuridine; Doxifluridinum; Doxifluridine; Doxyfluridine; Doxifluridina; Ro 21-9738; Ro 219738; 3094-09-5; Furtulon; 5-DFUrd; 5-DFUR; 5-Fluoro-5'-deoxyuridine; 5'-DFUR
数据库引用编号
15 个数据库交叉引用编号
- ChEBI: CHEBI:93756
- ChEBI: CHEBI:31521
- KEGG: C12739
- PubChem: 18343
- PubChem: 3159
- HMDB: HMDB0060406
- Metlin: METLIN44123
- DrugBank: DB12947
- ChEMBL: CHEMBL1130
- ChEMBL: CHEMBL6567
- CAS: 3094-09-5
- PMhub: MS000023158
- PubChem: 583128
- NIKKAJI: J7.679A
- medchemexpress: HY-B0021
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
3 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(2)
- Capecitabine Action Pathway:
Capecitabine + Water ⟶ 5'-Deoxy-5-fluorouridine + Meprobamate - Capecitabine Metabolism Pathway:
Capecitabine + Water ⟶ 5'-Deoxy-5-fluorouridine + Meprobamate
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Nastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, Fabienne Thomas, Florence Dalenc, Jean-Marc Ferrero, Xavier Pivot, Gérard Milano, Bernard Royer, Antonin Schmitt. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
Cancer chemotherapy and pharmacology.
2021 02; 87(2):229-239. doi:
10.1007/s00280-020-04208-8. [PMID: 33386926] - Penghua Li, Haiqing He, Yunqin Zhang, Rui Yang, Lili Xu, Zixi Chen, Yingying Huang, Limei Bao, Guozhi Xiao. Glycosyl ortho-(1-phenylvinyl)benzoates versatile glycosyl donors for highly efficient synthesis of both O-glycosides and nucleosides.
Nature communications.
2020 01; 11(1):405. doi:
10.1038/s41467-020-14295-z. [PMID: 31964883] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Masae Sekido, Ken-Ichi Fujita, Yutaro Kubota, Hiroo Ishida, Takehiro Takahashi, Ryotaro Ohkuma, Takuya Tsunoda, Fumihiro Ishikawa, Motoko Shibanuma, Yasutsuna Sasaki. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Cancer chemotherapy and pharmacology.
2019 06; 83(6):1127-1135. doi:
10.1007/s00280-019-03837-y. [PMID: 30972456] - Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, Chiara Cremolini, Fotios Loupakis, Federica Marmorino, Carlotta Antoniotti, Gianluca Masi, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Alfredo Falcone, Guido Bocci. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Investigational new drugs.
2018 08; 36(4):709-714. doi:
10.1007/s10637-018-0579-8. [PMID: 29488048] - Shinji Kobuchi, Yukiko Yazaki, Yukako Ito, Toshiyuki Sakaeda. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2018 Jan; 112(?):152-158. doi:
10.1016/j.ejps.2017.11.021. [PMID: 29175408] - Pan Deng, Cheng Ji, Xiaojian Dai, Dafang Zhong, Li Ding, Xiaoyan Chen. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 May; 989(?):71-9. doi:
10.1016/j.jchromb.2015.03.002. [PMID: 25808944] - Josephine Anthony, Vijaya Raghavan Rangamaran, Dharani Gopal, Kumar T Shivasankarasubbiah, Mary Leema J Thilagam, Magesh Peter Dhassiah, Divya Shridhar M Padinjattayil, VinithKumar N Valsalan, Vijayakumaran Manambrakat, Sivakumar Dakshinamurthy, Sivaraman Thirunavukkarasu, Kirubagaran Ramalingam. Ultraviolet and 5'fluorodeoxyuridine induced random mutagenesis in Chlorella vulgaris and its impact on fatty acid profile: a new insight on lipid-metabolizing genes and structural characterization of related proteins.
Marine biotechnology (New York, N.Y.).
2015 Feb; 17(1):66-80. doi:
10.1007/s10126-014-9597-5. [PMID: 25189135] - Andre Farkouh, Werner Scheithauer, Philipp Buchner, Apostolos Georgopoulos, Johannes Schueller, Birgit Gruenberger, Martin Czejka. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Anticancer research.
2014 Jul; 34(7):3669-73. doi:
NULL. [PMID: 24982385] - Veronika Schreiber, Marie Kitzmueller, Martina Poxhofer, Stefanie Gintersdorfer, Catharina Neudorfer, Maria Lichtneckert, Christian Dittrich, Martin Czejka. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Anticancer research.
2014 Jul; 34(7):3371-6. doi:
NULL. [PMID: 24982342] - In-Hwan Baek, Byung-Yo Lee, Min-Soo Kim, Kwang-Il Kwon. Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.
European journal of drug metabolism and pharmacokinetics.
2013 Dec; 38(4):295-9. doi:
10.1007/s13318-013-0130-4. [PMID: 23564503] - Vijaya L Damaraju, Delores Mowles, Marnie Wilson, Michelle Kuzma, Carol E Cass, Michael B Sawyer. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.
Biochemistry and cell biology = Biochimie et biologie cellulaire.
2013 Dec; 91(6):419-27. doi:
10.1139/bcb-2013-0041. [PMID: 24219283] - Philipp Buchner, Eva Mihola, Azra Sahmanovic, Tanja Steininger, Christian Dittrich, Martin Czejka. Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
Anticancer research.
2013 Mar; 33(3):881-6. doi:
. [PMID: 23482757] - Mikihiro Kusama. [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide(DMpC)combination therapy found effective for case of chest wall recurrent breast cancer with bone and pleural metastases].
Gan to kagaku ryoho. Cancer & chemotherapy.
2012 Aug; 39(8):1239-41. doi:
. [PMID: 22902449] - Martin Czejka, J Schueller, A Farkouh, B Gruenberger, W Scheithauer. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Cancer chemotherapy and pharmacology.
2011 Mar; 67(3):613-9. doi:
10.1007/s00280-010-1363-4. [PMID: 20495919] - Masao Kobayakawa, Yasushi Kojima. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.
OncoTargets and therapy.
2011; 4(?):193-201. doi:
10.2147/ott.s19059. [PMID: 22162925] - A Farkouh, J Schueller, W Scheithauer, M Czejka. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
International journal of clinical pharmacology and therapeutics.
2010 Jul; 48(7):487-8. doi:
10.5414/cpp48487. [PMID: 20557855] - Xiaofan Zhang, Julia Li Zhong, Wei Liu, Zuhua Gao, Xia Xue, Pan Yue, Limei Wang, Cuirong Zhao, Wenfang Xu, Xianjun Qu. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Cancer chemotherapy and pharmacology.
2010 May; 66(1):11-9. doi:
10.1007/s00280-009-1128-0. [PMID: 19756602] - Liia D Vainchtein, Hilde Rosing, Jan H M Schellens, Jos H Beijnen. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Biomedical chromatography : BMC.
2010 Apr; 24(4):374-86. doi:
10.1002/bmc.1302. [PMID: 19650151] - Shoichi Hazama, Atsushi Nagashima, Hiroshi Kondo, Shin Yoshida, Ryoichi Shimizu, Atsuhiro Araki, Shigefumi Yoshino, Naoko Okayama, Yuji Hinoda, Masaaki Oka. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Cancer science.
2010 Mar; 101(3):722-7. doi:
10.1111/j.1349-7006.2009.01428.x. [PMID: 20028383] - Takahiro Nakayama, Shinzaburo Noguchi. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
The oncologist.
2010; 15(1):26-36. doi:
10.1634/theoncologist.2009-0255. [PMID: 20080863] - Xingxing Kong, Heng Fan, Xiaojun Liu, Rui Wang, Jichao Liang, Nishith Gupta, Yong Chen, Fude Fang, Yongsheng Chang. Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5'-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase.
Molecular pharmacology.
2009 Oct; 76(4):854-60. doi:
10.1124/mol.109.056424. [PMID: 19602572] - Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda. Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.
The Tokai journal of experimental and clinical medicine.
2009 Sep; 34(3):106-11. doi:
. [PMID: 21319009] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - Young-Ah Woo, Ghee-Hwan Kim, Eun Ju Jeong, Choong-Yong Kim. Simultaneous determination of doxifluridine and 5-fluorouracil in monkey serum by high performance liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2008 Nov; 875(2):487-92. doi:
10.1016/j.jchromb.2008.09.037. [PMID: 18945647] - Reiki Nishimura, Takeshi Tominaga, Morihiko Kimura, Yasuhiro Yanagita, Nobumitsu Tamaki, Kazuaki Asaishi, Yasushi Okamoto, Nobuo Okuyama, Hideki Takeuchi, Masaharu Inaba, Takako Doi. Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Anti-cancer drugs.
2008 Oct; 19(9):911-5. doi:
10.1097/cad.0b013e3283099e71. [PMID: 18766005] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - W S Siegel-Lakhai, A S Zandvliet, A D R Huitema, M M Tibben, G Milano, V Girre, V Diéras, A King, E Richmond, J Wanders, J H Beijnen, J H M Schellens. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer.
2008 Apr; 98(8):1320-6. doi:
10.1038/sj.bjc.6604300. [PMID: 18414469] - Edward A Lock, Celia J Reed, Gilbert R Kinsey, Rick G Schnellmann. Caspase-dependent and -independent induction of phosphatidylserine externalization during apoptosis in human renal carcinoma Cak(1)-1 and A-498 cells.
Toxicology.
2007 Jan; 229(1-2):79-90. doi:
10.1016/j.tox.2006.10.003. [PMID: 17097791] - Mugunthu R Dhananjeyan, Jidong Liu, Crystal Bykowski, Jill A Trendel, Jeffrey G Sarver, Howard Ando, Paul W Erhardt. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Journal of chromatography. A.
2007 Jan; 1138(1-2):101-8. doi:
10.1016/j.chroma.2006.10.038. [PMID: 17070825] - Míriam Molina-Arcas, Gema Moreno-Bueno, Pedro Cano-Soldado, Héctor Hernández-Vargas, F Javier Casado, José Palacios, Marçal Pastor-Anglada. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.
Biochemical pharmacology.
2006 Dec; 72(12):1646-56. doi:
10.1016/j.bcp.2006.07.036. [PMID: 16965766] - Shin Mizutani, Tsukasa Oyama, Nobutaka Hatanaka, Fumihiro Uchikoshi, Katsuhide Yoshidome, Masayuki Tori, Shigeyuki Ueshima, Masaaki Nakahara, Kazuyasu Nakao. Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy.
International journal of clinical oncology.
2006 Dec; 11(6):471-4. doi:
10.1007/s10147-006-0597-y. [PMID: 17180517] - Hideyuki Honma. [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Dec; 33(13):2045-8. doi:
NULL. [PMID: 17197750] - Ryota Matsuo, Tadashi Kondo, Yukio Ohshiro, Yuomi Moon, Yuji Yamamoto, Tohru Takeshima, Takeshi Todoroki, Nobuhiro Ohkohchi. [A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Oct; 33(10):1501-4. doi:
NULL. [PMID: 17033247] - Junichi Gotoh, Hiromitsu Akabane, Kengo Kita, Masato Fujiyoshi, Gentaro Hirokata, Koji Imai, Tomoaki Kawai, Naoyuki Yanagida, Shiro Nakano, Masahiro Takahashi. [A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Sep; 33(9):1349-51. doi:
. [PMID: 16969040] - Yoshifumi Nakayama, Kentaro Matsumoto, Yuzuru Inoue, Takefumi Katsuki, Koji Kadowaki, Kazunori Shibao, Yosuke Tsurudome, Keiji Hirata, Tatsuhiko Sako, Naoki Nagata, Hideaki Itoh. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Anticancer research.
2006 Sep; 26(5B):3983-8. doi:
. [PMID: 17094430] - Saik Urien, Keyvan Rezaí, François Lokiec. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Journal of pharmacokinetics and pharmacodynamics.
2005 Dec; 32(5-6):817-33. doi:
10.1007/s10928-005-0018-2. [PMID: 16284918] - Sylvie M Guichard, Iain Mayer, Duncan I Jodrell. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Nov; 826(1-2):232-7. doi:
10.1016/j.jchromb.2005.09.010. [PMID: 16198157] - Jin-Fang Zheng, Hai-Dong Wang. 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
World journal of gastroenterology.
2005 Jul; 11(25):3944-7. doi:
10.3748/wjg.v11.i25.3944. [PMID: 15991299] - Susan Pratt, Robert L Shepard, Ramani A Kandasamy, Paul A Johnston, William Perry, Anne H Dantzig. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Molecular cancer therapeutics.
2005 May; 4(5):855-63. doi:
10.1158/1535-7163.mct-04-0291. [PMID: 15897250] - Toshiaki Saeki, Shigemitsu Takashima, Masanori Terashima, Atsushi Satoh, Masakazu Toi, Akihiko Osaki, Tetsuya Toge, Shinji Ohno, Naohiro Nomura, Yoshio Fukuyama, Wasaburo Koizumi, Tetsuo Taguchi. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
International journal of clinical oncology.
2005 Feb; 10(1):51-7. doi:
10.1007/s10147-004-0460-y. [PMID: 15729602] - Yoshinori Kato, Hiraku Onishi, Yoshiharu Machida. Contribution of chitosan and its derivatives to cancer chemotherapy.
In vivo (Athens, Greece).
2005 Jan; 19(1):301-10. doi:
. [PMID: 15796190] - Yuji Ueda, Hisakazu Yamagishi, Tetsuro Yamashita, Norio Itoh, Hirosumi Itoi, Tetsuhiko Shirasaka, Jaffer A Ajani. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Japanese journal of clinical oncology.
2004 May; 34(5):282-6. doi:
10.1093/jjco/hyh044. [PMID: 15231865] - R Morant, J Bernhard, D Dietrich, S Gillessen, M Bonomo, M Borner, J Bauer, T Cerny, C Rochlitz, M Wernli, A Gschwend, S Hanselmann, F Hering, H-P Schmid. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
British journal of cancer.
2004 Apr; 90(7):1312-7. doi:
10.1038/sj.bjc.6601673. [PMID: 15054447] - Hui-jun Wang, Hai Wang, Han-zhong Li, Bing-bing Shi, Zong-lu Song. [Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
Zhonghua wai ke za zhi [Chinese journal of surgery].
2004 Feb; 42(4):205-6. doi:
. [PMID: 15062035] - Patrick Schöffski. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Anti-cancer drugs.
2004 Feb; 15(2):85-106. doi:
10.1097/00001813-200402000-00001. [PMID: 15075664] - Shinichi Ikemoto, Kazunobu Sugimura, Naomasa Yoshida, Katsuyuki Kuratsukuri, Seiji Wada, Tatsuya Nakatani. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Urologia internationalis.
2004; 73(4):348-53. doi:
10.1159/000081597. [PMID: 15604581] - Y Yamada, T Hamaguchi, M Goto, K Muro, Y Matsumura, Y Shimada, K Shirao, S Nagayama. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
British journal of cancer.
2003 Sep; 89(5):816-20. doi:
10.1038/sj.bjc.6601224. [PMID: 12942110] - Tomoaki Yoshino, Yoshiharu Machida, Hiraku Onishi, Tsuneji Nagai. Preparation and characterization of chitosan microspheres containing doxifluridine.
Drug development and industrial pharmacy.
2003 Apr; 29(4):417-27. doi:
10.1081/ddc-120018377. [PMID: 12737535] - Kazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, Hitomi Suda, Masako Ura, Tohru Ishikawa, Masanori Miwa, Mika Endoh, Hiroyuki Eda, Hiromi Tanimura, Akira Kawashima, Ikuo Horii, Hideo Ishitsuka, Nobuo Shimma. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Bioorganic & medicinal chemistry letters.
2003 Mar; 13(5):867-72. doi:
10.1016/s0960-894x(02)01082-x. [PMID: 12617910] - Ronald Gieschke, Hans-Ulrich Burger, Bruno Reigner, Karen S Blesch, Jean-Louis Steimer. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
British journal of clinical pharmacology.
2003 Mar; 55(3):252-63. doi:
10.1046/j.1365-2125.2003.01765.x. [PMID: 12630975] - Hiroki Konishi, Takashi Yoshimoto, Kunihiko Morita, Tokuzo Minouchi, Takashi Sato, Akira Yamaji. Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats.
The Journal of pharmacy and pharmacology.
2003 Jan; 55(1):143-9. doi:
10.1211/002235702298. [PMID: 12625878] - Shinichi Ikemoto, Kazunobu Sugimura, Naomasa Yoshida, Katsuyuki Kuratsukuri, Seiji Wada, Tatsuya Nakatani. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon gamma in renal cell carcinoma cell lines.
Anticancer research.
2002 Nov; 22(6C):4023-7. doi:
. [PMID: 12553027] - Hiroki Konishi, Kunihiko Morita, Tokuzo Minouchi, Masayuki Nakajima, Masayuki Matsuda, Akira Yamaji. Probable metabolic interaction of doxifluridine with phenytoin.
The Annals of pharmacotherapy.
2002 May; 36(5):831-4. doi:
10.1345/aph.1a354. [PMID: 11978162] - Yasuhiro Hirano, Tatsuya Takayama, Shinji Kageyama, Tomomi Ushiyama, Kazuo Suzuki, Kimio Fujita. Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Urological research.
2002 May; 30(2):112-5. doi:
10.1007/s00240-002-0241-x. [PMID: 12086015] - Katsumasa Kuroi, Takeshi Tominaga. [Sustained complete response in lung metastasis of breast cancer by goserelin--report of two cases].
Gan to kagaku ryoho. Cancer & chemotherapy.
2002 Apr; 29(4):589-94. doi:
. [PMID: 11977544] - John R Mackey, Lori L Jennings, Marilyn L Clarke, Cheryl L Santos, Laith Dabbagh, Michaela Vsianska, Sheryl L Koski, Robert W Coupland, Stephen A Baldwin, James D Young, Carol E Cass. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Jan; 8(1):110-6. doi:
. [PMID: 11801546] - Y Chino, Y Suzuki, N Ubukata, K Yoshihara, T Tani, M Ogata. [Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Gan to kagaku ryoho. Cancer & chemotherapy.
2001 Nov; 28(12):1897-9. doi:
. [PMID: 11729483] - A Ooi, T Ohkubo, M Higashigawa, H Kawasaki, H Kakito, Y Kagawa, M Kojima, M Sakurai. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Biological & pharmaceutical bulletin.
2001 Nov; 24(11):1329-31. doi:
10.1248/bpb.24.1329. [PMID: 11725974] - S Yamamoto, J Kurebayashi, M Kurosumi, H Kunisue, T Otsuki, K Tanaka, H Sonoo. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Cancer chemotherapy and pharmacology.
2001 Oct; 48(4):283-8. doi:
10.1007/s002800100325. [PMID: 11710628] - H Satoh, T Okhi, T Momma, S Saito, H Niizeki, S Hirose, S Kuramochi. [Penile skin metastasis of gastric carcinoma associated with prostate carcinoma: a case report].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
2001 Sep; 92(6):628-31. doi:
10.5980/jpnjurol1989.92.628. [PMID: 11593706] - A Gadducci, S Cosio, A Fanucchi, A R Genazzani. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management.
Anticancer research.
2001 Jul; 21(4B):2941-7. doi:
. [PMID: 11712791] - J F Mata, J M García-Manteiga, M P Lostao, S Fernández-Veledo, E Guillén-Gómez, I M Larrayoz, J Lloberas, F J Casado, M Pastor-Anglada. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Molecular pharmacology.
2001 Jun; 59(6):1542-8. doi:
10.1124/mol.59.6.1542. [PMID: 11353816] - T Morita, A Matsuzaki, A Tokue. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
International journal of cancer.
2001 May; 92(3):451-6. doi:
10.1002/ijc.1212. [PMID: 11291085] - Y Basaki, L Chikahisa, K Aoyagi, K Miyadera, K Yonekura, A Hashimoto, S Okabe, K Wierzba, Y Yamada. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Angiogenesis.
2001; 4(3):163-73. doi:
10.1023/a:1014059528046. [PMID: 11911014] - Y Tsukamoto, Y Kato, M Ura, I Horii, T Ishikawa, H Ishitsuka, Y Sugiyama. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Biopharmaceutics & drug disposition.
2001 Jan; 22(1):1-14. doi:
10.1002/bdd.250. [PMID: 11745902] - R Sumimoto, M Takahashi, T Etoh, Y Ichiba, K Emoto, Y Imaoka, Y Ishizaki, N Tokumoto. [Effectiveness of high-dose, intermittent 5'-DFUR therapy for advanced gastric cancer].
Gan to kagaku ryoho. Cancer & chemotherapy.
2001 Jan; 28(1):83-6. doi:
NULL. [PMID: 11201386] - H J Hussey, P T Todorov, W N Field, N Inagaki, Y Tanaka, H Ishitsuka, M J Tisdale. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
British journal of cancer.
2000 Jul; 83(1):56-62. doi:
10.1054/bjoc.2000.1278. [PMID: 10883668] - K Kuwata, S Nagayama, Y Hirakawa, E Matsushima, Y Kawaguchi. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Gan to kagaku ryoho. Cancer & chemotherapy.
2000 Jun; 27(6):885-90. doi:
. [PMID: 10897216] - S Oura, T Sakurai, G Yoshimura, T Tamaki, T Umemura, Y Kokawa, Y Naito. [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
Gan to kagaku ryoho. Cancer & chemotherapy.
2000 Apr; 27(4):633-7. doi:
NULL. [PMID: 10791010] - S Yamamoto, J Kurebayashi, H Kunisue, K Udagawa, Y Yamamoto, I Arime, K Tanaka, K Shimozuma, H Sonoo. [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model].
Gan to kagaku ryoho. Cancer & chemotherapy.
1999 Sep; 26(10):1443-8. doi:
. [PMID: 10500532] - K Yonekura, Y Basaki, L Chikahisa, S Okabe, A Hashimoto, K Miyadera, K Wierzba, Y Yamada. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1999 Aug; 5(8):2185-91. doi:
NULL. [PMID: 10473104] - K Hoshino, M Nakamura, H Ikeda, T Koyama, Y Morishita. [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Gan to kagaku ryoho. Cancer & chemotherapy.
1999 Jun; 26(7):983-7. doi:
NULL. [PMID: 10396328] - S A Van Der Heyden, M S Highley, E A De Bruijn, U R Tjaden, H J Reeuwijk, H Van Slooten, A T Van Oosterom, R A Maes. Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
British journal of clinical pharmacology.
1999 Apr; 47(4):351-6. doi:
10.1046/j.1365-2125.1999.00899.x. [PMID: 10233196] - Y Hirano, T Ushiyama, K Suzuki, K Fujita. [Interferons alpha-2a and gamma increase the antitumor activity, detected by histoculture drug response assay, of doxifluridine against clinical renal cell cancers].
Gan to kagaku ryoho. Cancer & chemotherapy.
1999 Mar; 26(4):557-9. doi:
NULL. [PMID: 10097758] - D P Stevenson, W P Collins, F Farzaneh, K Hata, K Miyazaki. Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
The American journal of pathology.
1998 Nov; 153(5):1573-8. doi:
10.1016/s0002-9440(10)65745-8. [PMID: 9811349] - Y Hirano, T Takayama, T Ushiyama, K Suzuki, K Fujita. [The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
Gan to kagaku ryoho. Cancer & chemotherapy.
1998 Sep; 25(11):1779-81. doi:
NULL. [PMID: 9757207] - C G Zambonin, S Mastrolitti, F Palmisano. Determination of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxifluridine, in body fluids by high performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis.
1998 Jun; 17(2):291-7. doi:
10.1016/s0731-7085(97)00200-8. [PMID: 9638582] - K Kan, K Naitoh, A Tsuruta, N Mizuta, K Ohmori, H Kawachi, H Amaike, M Yanada, Y Ohmori. [A CR case of amylase-producing tumor treated by hyperthermochemotherapy].
Gan to kagaku ryoho. Cancer & chemotherapy.
1998 Mar; 25(4):577-80. doi:
NULL. [PMID: 9530365] - B Satoh, M Ohtoshi, Y Ishida, K Hen-mi, I Kaneko, M Soda, J Sugihara, F Shibagaki, N Iwai, T Nakamura, T Yamasaki, S Matsumoto. [Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area].
Gan to kagaku ryoho. Cancer & chemotherapy.
1998 Feb; 25(3):359-64. doi:
. [PMID: 9492829] - M Takita, M Onda, A Tokunaga, T Shirakawa, K Ikeda, Y Hiramoto, T Teramoto, T Oguri, I Fujita, T Okuda, T Mizutani, T Kiyama, T Yoshiyuki, N Matsukura. [Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan].
Gan to kagaku ryoho. Cancer & chemotherapy.
1998 Jan; 25(1):129-33. doi:
NULL. [PMID: 9464340] - G Nishimura, R Izumi, N Matsuki, S Takeyama, K Konishi, H Fujita, R Miyata, T Sasaki, Y Kojima, M Takada, Y Takita, M Kanno, K Ueno, T Mura, K Asano, M Syouji, H Yamazaki, T Ooto, H Ueda, Y Takigawa, T Sawa, I Miyazaki. [Effect on 5'-deoxy-5-fluorouridine (5'-DFUR) of pyrimidine nucleoside phosphorylase (PyNPase), matrix metalloprotease and serum IAP values. Hokuriku Colorectal Cancer Chemotherapy Study Group].
Gan to kagaku ryoho. Cancer & chemotherapy.
1997 Oct; 24(13):1947-52. doi:
. [PMID: 9350241] - N Murakami, M Hirano, H Saito, S Nagao, Y Arano, T Kikuchi, N Ishikawa, M Kurokawa, H Kitsukawa. [Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)].
Gan to kagaku ryoho. Cancer & chemotherapy.
1996 Dec; 23(14):1959-66. doi:
. [PMID: 8978804] - H Iwagaki, A Hizuta, T Fujiwara, J A Perdomo, N Tanaka, K Orita. Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy.
Acta medica Okayama.
1996 Oct; 50(5):271-2. doi:
10.18926/amo/30494. [PMID: 8914681] - C G Zambonin, F Palmisano. Gas chromatography-mass spectrometry identification of a novel N3-methylated metabolite of 5'-deoxy-5-fluorouridine in plasma of cancer patients undergoing chemotherapy.
Journal of pharmaceutical and biomedical analysis.
1996 Aug; 14(11):1521-8. doi:
10.1016/0731-7085(96)01798-0. [PMID: 8877858] - A Hamada, S Fukushima, M Saneyoshi, S Shimizu, T Kawaguchi, M Nakano. Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Biological & pharmaceutical bulletin.
1996 May; 19(5):729-32. doi:
10.1248/bpb.19.729. [PMID: 8741584] - H Tsuzuki, M Niki, H Ueda, H Abe, Y Kurosu. [Successful combination chemotherapy for a post-operative gastric cancer patient with multiple liver metastases and elevated CEA].
Gan to kagaku ryoho. Cancer & chemotherapy.
1996 May; 23(6):779-81. doi:
NULL. [PMID: 8645029] - Y Tanaka, M Ogino, H Tokuda, M Mizuno, M Yamauchi. [A case of hepatocellular carcinoma responding to oral administration of 5'-DFUR].
Gan to kagaku ryoho. Cancer & chemotherapy.
1996 Mar; 23(4):483-6. doi:
. [PMID: 8678502] - T Kirita, K Hamano, G Mabuchi, A Seshimo, A Kawase, M Miyashita, N Inada. [Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values].
Gan to kagaku ryoho. Cancer & chemotherapy.
1995 Mar; 22(4):509-14. doi:
. [PMID: 7887642] - M Suzuki, I Aida, M Ohwada, I Sato, T Tamura, Y Kasuga. [5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer].
Gan to kagaku ryoho. Cancer & chemotherapy.
1995 Feb; 22(2):253-8. doi:
NULL. [PMID: 7857101] - K Miyazaki, H Yakushiji, K Kitahara, M Mori, E Sasatomi, N Tsutsumi, Y Hirohashi, A Iwanaga, A Iyama, H Fukagawa. [A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
Gan to kagaku ryoho. Cancer & chemotherapy.
1994 Apr; 21(5):641-5. doi:
NULL. [PMID: 8154890] - A Hamada, S Fukushima, A Morinaga, M Saneyoshi, T Kawaguchi, M Nakano. Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Biological & pharmaceutical bulletin.
1993 Dec; 16(12):1297-300. doi:
10.1248/bpb.16.1297. [PMID: 8130783] - A Guerrieri, F Palmisano, P G Zambonin, M De Lena, V Lorusso. Solid-phase extraction of fluoropyrimidine derivatives on a copper-modified strong cation exchanger: determination of doxifluridine, 5-fluorouracil and its main metabolites in serum by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography.
1993 Jul; 617(1):71-7. doi:
10.1016/0378-4347(93)80423-2. [PMID: 8376540] - H Yuan, Z Zhang. Some factors affecting sister-chromatid differentiation (SCD) and sister-chromatid exchange (SCE) in Hordeum vulgare.
Mutation research.
1992 Oct; 272(2):125-31. doi:
. [PMID: 1383744] - J Koh, Y Murayama, M Sano, H Katai, K Maeda, S Sakai, O Yamamoto, M Hashimoto, Y Hosoda. [A case of advanced breast cancer responding to low-dose 5'-DFUR].
Gan to kagaku ryoho. Cancer & chemotherapy.
1992 Jul; 19(7):1063-6. doi:
NULL. [PMID: 1385689] - H Maeda, T Miyamoto, N Mochinaga, T Tsunoda. [5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Gan to kagaku ryoho. Cancer & chemotherapy.
1991 May; 18(6):965-9. doi:
NULL. [PMID: 1827573] - M Nozue, T Todoroki, H Ueda, S Fukuda, H Miyamoto, Y Kawai, Y Iwasaki. [5-fluorouracil concentration in gastroenterological tumor tissues, in adjacent normal tissues, and in serum after preoperative oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Gan to kagaku ryoho. Cancer & chemotherapy.
1991 Mar; 18(3):377-82. doi:
NULL. [PMID: 1825909] - K Ishiwata, K Sato, M Kameyama, T Yoshimoto, T Ido. Metabolic fates of 2'-deoxy-5-[18F]fluorouridine in tumor-bearing mice and human plasma.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
1991; 18(5):539-45. doi:
10.1016/0883-2897(91)90115-2. [PMID: 1833361]